Migraine is a debilitating neurological condition affecting millions of people worldwide. Until
a few years ago, preventive migraine treatments were based on molecules with pleiotropic …

Migraine stands as one of the most disabling neurological conditions worldwide. It is a
disorder of great challenge to study given its heterogeneous representation, cyclic nature …

Background Ubrogepant, a small-molecule calcitonin gene-related peptide receptor
antagonist, was recently approved as an oral medication for the acute treatment of migraine …

Medication overuse headache is estimated to affect 2% of the population, and is ranked in
the top 20 most disabling disorders due to its high level of disability. Several therapies used …

Migraine is a common and disabling neurological disorder, with several manifestations, of
which pain is just one. Despite its worldwide prevalence, there remains a paucity of targeted …

Introduction Clinically, calcitonin gene-related peptide antagonising drugs are recognized
as effective in migraine treatment, but their site of action is debated. Only a small fraction of …

Introduction Rodent disease models can play an indispensable role in drug development.
Confirming that translationally-relevant disease mechanisms are engaged in such models is …

Preclinical data point to the contribution of transient receptor potential ankyrin 1 (TRPA1)
channels to the complex mechanisms underlying migraine pain. TRPA1 channels are …

Background Recently, the adenosine triphosphate (ATP) sensitive potassium channel
opener levcromakalim was shown to induce migraine attacks with a far higher incidence …

Objective The aim of this study was to evaluate whether elevating levels of enkephalin by
inhibiting their degradation can attenuate stress‐induced migraine‐like behaviors in mice …